Observational Study of First-Line Treatments for Metastatic Urothelial Carcinoma Identifying Patient Characteristics and Treatment Choices After 2024

What this Trial Is About

Researchers are studying patients with metastatic urothelial carcinoma to understand the characteristics and treatment choices for first-line metastatic therapy in real-world settings. This observational, multicenter study aims to identify why clinicians choose platinum-based chemotherapy over the newer combination of Enfortumab Vedotin and Pembrolizumab for some patients. The study builds on recent findings from the EV-302 trial and focuses on treatment decisions made since late 2024. Participants included in this study are those who have received first-line metastatic treatment since October 2024. The study does not involve administering treatments but observes and records the therapies patients have received in routine clinical practice. The main treatment options under observation are the combination of Enfortumab Vedotin and Pembrolizumab versus platinum-based chemotherapy with or without avelumab. During the study, researchers will collect data on patient clinical characteristics and treatment details for up to 12 months. The primary outcome is to describe these characteristics and understand treatment choices. Since this is an observational study, participants will not undergo additional interventions but will be monitored through data collection. The study is sponsored by the University Hospital in Strasbourg, France, and will run until April 2026.

Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma